Notably, pharmacological inhibition of Cx HCs in vitro and genetic ablation of Cx43 in vivo improves motor neuron survival in mutSOD1 ALS models, highlighting their potential as therapeutic targets (Almad et al., 2016; Almad et al., 2022). Here, GJA1 is linked to amyotrophic lateral sclerosis.